Business UpdateJul 16, 2026, 08:01 AM
Gain Therapeutics Funds Operations into Q2 2027
AI Summary
Gain Therapeutics, Inc. announced on July 16, 2026, that its current cash and cash equivalents are expected to fund operations into the second quarter of 2027. This projection is based on current operating plans, which include the completion of a Phase 1b open-label extension in October 2026 and the initiation of a Phase 2 clinical study during the third quarter of 2026.
Key Highlights
- Anticipates cash and cash equivalents to fund operations into Q2 2027.
- Funding projection based on current operating plans.
- Includes completion of Phase 1b open-label extension in October 2026.
- Includes initiation of a Phase 2 clinical study during Q3 2026.
- Announcement made via press release and shareholder letter on July 16, 2026.
Price Impact
More from GANX